Investor Presentaiton

467 Segmental Revenue Breakup Generics API 571 522 424 359 160 Generics FDF 292 267 352 452 85 78 Cr Synthesis 148 116 100 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 Q1 Q2 Q2 FY20 FY20 FY20 FY21 FY21 FY20 FY20 FY20 FY21 FY21 FY20 FY20 Q3 Q4 FY20 Q1 Q2 FY21 FY21 Generic API division showcased a healthy growth of 22% YoY Anti Viral segment recorded growth of 20% YoY Q2 FY 21 Contribution 40% Generic FDF Revenue Showcased a robust growth of 183% YoY 50% The growth was led by higher LMIC Market volumes and increased volumes from North America and EU Commenced marketing of in-licensed products in the USA to leverage front-end capabilities 10% Custom Synthesis division recorded a strong growth of 36% YoY ■Generics API ■ Synthesis ■Generics FDF 5 LAURUS Labs Knowledge Innovation. Excelence

View entire presentation